Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.

Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of WHO II and III Grade Incident Gliomas.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04461002

Enrollment

Registered

2020-07-08

Start date

2019-09-30

Completion date

2024-06-30

Last updated

2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Brief summary

From the medical records of a series of patients operated on for incident grade II and III glioma, the primary objective is to evaluate the correlation between the molecular profile of tumours and preoperative imaging data (by FDG and FDOPA PET-scan and multimodal MRI).

Detailed description

A retrospective monocentre study of medical data (clinical, histological, molecular and imaging) contained in the medical records of patients operated on for Grade II or III incident glioma.

Interventions

OTHERRetrospective analysis

Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject 18 years of age or older, having been informed of the research * Subject operated on with an incident glioma of grade II or III, histologically confirmed (WHO 2016 classification) * Subject for which all preoperative imaging data is available (MRI, FDG and FDOPA PET-scan) * Subject for which molecular data of the lesion are available

Exclusion criteria

* Subject having signified his opposition to the use of his medical data * Subject under safeguard of justice, guardianship or trusteeship * Subject with incomplete or missing part of the molecular and/or imaging data

Design outcomes

Primary

Measure	Time frame	Description
Primary outcome	4 years	Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).

Secondary

Measure	Time frame	Description
Molecular profile	4years	Evaluate the overall survival and progression-free survival of patients based on the molecular profile of gliomas.
Imaging data	4 years	To evaluate the overall survival and progression-free survival of patients based on imaging data (PET-scan and MRI) of gliomas.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026